Main Uses of Adcal-D3

Adcal-D3 is a combination supplement containing two active ingredients: calcium carbonate and vitamin D3 (colecalciferol). It is primarily used to manage conditions where the body requires additional calcium and vitamin D to maintain bone health and physiological function.

Treatment of Deficiencies

The supplement is used to treat and prevent calcium and vitamin D deficiency. These nutrients are essential for the maintenance of normal bones and teeth. A deficiency may occur due to dietary restrictions, lack of exposure to sunlight, or malabsorption issues.

Support for Bone Health

Adcal-D3 is frequently used as an adjunct to specific treatments for osteoporosis. Osteoporosis is a condition characterized by thinning of the bones, making them fragile and more likely to break. In these cases, the supplement ensures that the body has a sufficient supply of the building blocks necessary to support bone density and strength.

Benefits of Combined Therapy

The combination of calcium and vitamin D3 provides specific advantages for musculoskeletal health:

• Calcium Absorption: Vitamin D3 plays a critical role in the regulation of calcium levels in the body. It is required for the efficient absorption of calcium from the intestines into the bloodstream.
• Bone Mineralization: Calcium is the primary mineral stored in the bone matrix. By providing an adequate supply of calcium, the supplement supports the structural integrity of the skeletal system.
• Neuromuscular Support: Beyond bone health, calcium and vitamin D are involved in normal muscle function and nerve transmission. Maintaining adequate levels can help support overall physical stability, particularly in older populations.

Regulatory References

1. NIH MedlinePlus overview of Cholecalciferol

Who Can and Cannot Use Adcal-D3?

The population eligibility for Adcal-D3 is strictly defined by regulatory documents, primarily focusing on mineral status, organ function, and hypersensitivity. The medicine is indicated for use in adults and the elderly.

---

Official Contraindications

Adcal-D3 must not be used by individuals with specific conditions or sensitivities, as defined in the regulatory label. These contraindications include:

• Hypercalcaemia (high blood calcium levels) or severe hypercalciuria (high urine calcium levels).
• Severe renal failure or a history of renal stones (nephrolithiasis).
• Known hypersensitivity or allergy to the active ingredients (Calcium Carbonate, Colecalciferol) or any excipients, including a contraindication for soya or peanut allergy.
• Established Vitamin D overdosage.

---

Restrictions and Conditional Use

• Age Restriction: Use is not recommended in children under 12 years of age.
• Organ Function: Patients with mild to moderate renal impairment require close supervision and periodic monitoring of calcium levels and kidney function.
• Pregnancy and Lactation: Use during these periods is permitted only under strict medical supervision and careful monitoring of total Vitamin D and calcium intake.

Official Interaction Restrictions

The official interaction profile for Adcal-D3 (Calcium Carbonate and Colecalciferol) is structured by the ability of its calcium component to alter the systemic exposure of co-administered medicinal products and the potential for certain drugs to reinforce its physiological effects.

Mandatory Timing Separation

To prevent reduced systemic exposure of co-administered medicines, official regulatory documents require a mandatory separation of administration by a minimum of four hours from Adcal-D3 for several agents, including tetracycline and quinolone antibiotics, bisphosphonates (such as alendronate), levothyroxine, and iron salts. Additionally, absorption of the Colecalciferol (Vitamin D3) component is reduced by substances that interfere with fat-soluble vitamin uptake, such as orlistat and bile acid sequestrants.

Pharmacodynamic and Metabolic Interactions

Co-administration with thiazide diuretics increases the risk of hypercalcaemia due to reduced urinary calcium excretion. This risk is particularly critical for patients receiving cardiac glycosides (e.g., Digitalis), where increased calcium levels may accentuate the glycoside’s effects, potentially raising the risk of cardiac arrhythmias, which requires careful clinical monitoring. Furthermore, the effect of Colecalciferol is decreased by drugs that enhance its metabolic breakdown, such as phenytoin and barbiturates. Dietary interactions include a required separation of at least two hours from foods rich in oxalic or phytic acid to prevent reduced calcium absorption.

Adcal-D3 delivers calcium carbonate and cholecalciferol (Vitamin D3) for systemic absorption.

Calcium Component

Calcium carbonate dissociates in the gastric environment to elemental calcium ions (Ca^2+). These ions are absorbed primarily in the small intestine via both paracellular diffusion and a saturable, transcellular pathway. Systemically, Ca^2+ acts as a fundamental second messenger and structural component, maintaining the physiological integrity of cell membranes, nerve conduction, muscle contraction, and coagulation cascades.

---

Cholecalciferol Component

Cholecalciferol is metabolically inert until it undergoes 25-hydroxylation in the liver by CYP2R1 to form calcifediol (25-hydroxycholecalciferol). Calcifediol then undergoes a second hydroxylation in the kidney, catalyzed by the enzyme 1-alpha-hydroxylase (CYP27B1), to yield the biologically active form, calcitriol (1,25-dihydroxycholecalciferol). Calcitriol acts as an agonist at the Vitamin D Receptor (VDR), a nuclear receptor found in the intestinal mucosa, bone, and kidney.

This calcitriol-VDR complex functions as a transcription factor, binding to Vitamin D Response Elements (VDREs) on target genes. In the small intestine, VDR activation upregulates the transcription of transport proteins, including the epithelial calcium channel TRPV6 and the calcium-binding protein calbindin. This intracellular cascade results in increased active absorption of Ca^2+ and phosphate across the gut, leading to an overall systemic modulation of calcium and phosphate homeostasis.

How to Use Adcal-D3: Official Administration Guidelines

Adcal-D3 is an oral combination supplement, and its correct administration is defined by specific procedural and timing instructions.

---

Standard Dosing and Frequency

Population	Standard Dosing Regimen	Frequency and Timing
Adults and Elderly	Two tablets/units daily, providing 1200 mg elemental calcium and 800 IU Vitamin D3.	The dose is typically divided and taken twice daily, often recommended as one unit in the morning and one in the evening.
Children	Not recommended for children under 12 years of age.	N/A

---

Administration and Timing Instructions

The proper method of taking Adcal-D3 depends on the specific form:

• Chewable Tablets: Must be fully chewed before swallowing; do not swallow the tablets whole.
• Effervescent Tablets (Dissolve): Must be dissolved completely in a glass of water and the resulting solution drunk immediately; do not chew or swallow the tablet whole.

To ensure proper absorption, the instructions require specific time separation from certain foods and other medicines:

• Food Separation: The supplement should not be taken within two hours of consuming foods known to be rich in oxalic acid (e.g., spinach, rhubarb) or phytic acid (e.g., whole cereals).
• Drug Separation: A minimum period of approximately four hours must be allowed between taking Adcal-D3 and certain other oral medications, such as thyroxine, bisphosphonates, or tetracycline and quinolone antibiotics.

If a dose is missed, patients are instructed to take the missed dose as soon as possible, but not to take a double dose to compensate.

Research evidence / Overview of studies for Adcal-D3

---

Evidence for use in Correcting Calcium and Vitamin D Deficiencies

Research examining the combination of calcium and Vitamin D is based on biochemical studies and observational settings. These studies primarily monitored changes in key blood markers following supplementation in populations with diagnosed deficits. The findings describe patterns where the supplement was associated with increases in Vitamin D levels and shifts in calcium levels. Research has also explored how the combination was associated with shifts toward the normalization of parathyroid hormone (PTH) levels. While the evidence supporting the combination's use in deficiencies is documented in regulatory summaries, comparative evidence is lacking in some areas when evaluating it against other nutritional strategies.

Evidence for use as Adjunctive Therapy in Osteoporosis and Fracture Risk

Research was studied for this combination as adjunct therapy alongside specific osteoporosis treatments, largely based on Randomized Controlled Trials (RCTs) and systematic reviews. Researchers monitored endpoints like the incidence of new fractures and Bone Mineral Density (BMD) measurements. The findings describe patterns where the combination was observed in trials to be associated with changes in BMD. However, evidence concerning fracture prevention across all groups is not consistently clear, with subgroup findings uncertain between high-risk, institutionalized patients and community-dwelling older adults.

Study Limitations and Context

Clinical trials for this combination often involve long-term follow-up periods of two to four years, as these durations reflect the extended time intervals required to observe changes in skeletal structure and fracture rates. Long-term effects are not fully established beyond the trial periods. Research has indicated that the results apply only to the populations studied. The patterns observed may be more pronounced in the higher-risk, institutionalized groups who are at greater risk of deficiency. The overall evidence landscape has documented areas where certainty remains low, largely due to the heterogeneity of findings across different systematic reviews and comparative evidence being lacking in certain contexts.

Key Studies & References

1. Public Assessment Report: Reclassification of Calci-D 1000mg/1000 IU chewable tablets from Prescription Only Medicine to Pharmacy medicine (MHRA/GOV.UK)

Common questions about Adcal-D3 (FAQ)

Q: What is Adcal-D3 used for?

Adcal-D3 is a supplement used to prevent and treat calcium and vitamin D deficiency. It may also be prescribed as a supplement alongside specific treatments for osteoporosis (thinning of the bone).

---

Q: How should I take Adcal-D3?

It is typically recommended to chew or suck the tablets. Do not swallow them whole. Always follow the specific instructions given by your healthcare provider or those listed on the packaging. Adcal-D3 should be taken at the time prescribed by your doctor.

---

Q: What are the main ingredients in Adcal-D3?

The main active ingredients in Adcal-D3 are calcium carbonate (a form of calcium) and colecalciferol (also known as vitamin D3). These ingredients work together to increase the body's levels of calcium and vitamin D.

---

Q: What should I do if I forget to take a dose?

If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, you should skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one.

---

Q: Can I take Adcal-D3 if I am pregnant or breastfeeding?

Adcal-D3 can often be used during pregnancy and breastfeeding to supplement calcium and vitamin D, but only if directed by your doctor. High doses of vitamin D must be avoided during pregnancy. You should always discuss the use of any medication or supplement, including Adcal-D3, with your healthcare provider while pregnant or breastfeeding.

---

Q: What are the potential side effects of Adcal-D3?

Like many medicines, Adcal-D3 may cause side effects, although not everybody gets them. Common side effects can include:

• Constipation
• Flatulence (wind)
• Nausea (feeling sick)
• Stomach pain

Less common side effects may involve a raised amount of calcium in your blood (hypercalcaemia) or urine (hypercalciuria). You should contact your doctor if you experience any concerning side effects.

Official Storage and Disposal Requirements

Adcal-D3 must be stored strictly according to the conditions defined in regulatory labeling to maintain the stability of the Calcium Carbonate and Colecalciferol active ingredients.

Storage Conditions

The required storage temperature for Adcal-D3 chewable tablets is below 25°C, while specific effervescent tablet forms must be stored not above 30°C. The medicine must be kept out of the sight and reach of children.

Certain products require being stored in the original package, and effervescent tablet containers must be kept tightly closed to protect them from moisture. The product should not be used after the printed expiry date.

Disposal Instructions

Regulatory instructions mandate that unused or expired Adcal-D3 must not be thrown away via wastewater or household waste. The proper disposal procedure is to ask the pharmacist for guidance on discarding the medicine safely, which helps protect the environment.